Darolutamide in combination with androgen deprivation therapy (ADT) demonstrated significant benefit for patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to recent findings from the phase 3 ARANOTE trial. Bayer recently announced that the trial met its primary end point of radiological progression-free survival (rPFS), with the combination providing a clinically meaningful increase in rPFS compared with placebo plus ADT. ...
mCSPC
Advertisement
Dr. Lowentritt sheds light on a real-world comparison of PSA response in patients with mCSPC treated with apalutamide.
Intensified androgen blockade improves PSA progression-free survival in prostate cancer without affecting quality of life.
The ArteraAI MMAI prognostic biomarker performs risk stratification of patients with localized prostate cancer.
Researchers evaluated differences in treatment intensification and overall survival between patient groups.
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
Researchers performed a post hoc analysis on patient data from the randomized, phase 3 LATITUDE trial.
A combination of androgen annihilation therapy with radiotherapy was tested for recurrent metastatic prostate cancer.
Investigators evaluated the data of 427 patients with metastatic HSPC and serum initial PSA greater than 100 ng/ml.
Advertisement
Prostate Cancer Knowledge Hubs
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2024/06/122-GUOnc_YouTube_Sartor_1280x720.jpg)
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Advertisement
Advertisement
Latest News
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
Researchers focused on the economic impact of disparities related to insurance coverage.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
